903
Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients.
 postmenopausal node-positive breast cancer patients: Subject; Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently: Treatment; tamoxifen: Treatment.Drug; Epirubicin-cyclophosphamide: Treatment.Drug; node-positive breast cancer: Treatment.Disorder; tamoxifen: Combination.Drug; Epirubicin-cyclophosphamide: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 postmenopausal node-positive breast cancer patients: Subject; Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently: Treatment; tamoxifen: Treatment.Drug; Epirubicin-cyclophosphamide: Treatment.Drug; node-positive breast cancer: Treatment.Disorder; tamoxifen: Combination.Drug; Epirubicin-cyclophosphamide: Combination.Drug